Montelukast (sodium salt) – 500 mg

Brand:
Cayman
CAS:
151767-02-1
Storage:
-20
UN-No:
Non-Hazardous - /

Montelukast is a cysteinyl leukotriene 1 (CysLT1) receptor antagonist (IC50 = 4.9 nM in HEK293 cell membranes expressing the human receptor).{14081} It is selective for CysLT1 over CysLT2 receptors (IC50 = >10,000 nM in COS-7 cell membranes expressing the human receptor).{8519} Montelukast inhibits bronchoconstriction induced by leukotriene D4 (LTD4; Item No. 20310) in anesthetized guinea pigs (ED50 = 69 nmol/kg, p.o.).{10911} It inhibits ovalbumin-induced airway hyperresponsiveness and increases in the number of total cells and eosinophils in bronchoalveolar lavage fluid (BALF) in a mouse model of allergic asthma when administered at doses of 3 and 10 mg/kg.{11231} Formulations containing montelukast have been used in the treatment of asthma, allergic rhinitis, and exercise-induced bronchoconstriction.  

 

Available on backorder

SKU: 10008318 - 500 mg Category:

Description

A CysLT1 receptor antagonist (IC50 = 4.9 nM in HEK293 cell membranes expressing the human receptor); selective for CysLT1 over CysLT2 receptors (IC50 = >10,000 nM in COS-7 cell membranes expressing the human receptor); inhibits LTD4-induced bronchoconstriction in anesthetized guinea pigs (ED50 = 69 nmol/kg, p.o.); inhibits ovalbumin-induced airway hyperresponsiveness and increases in the number of total cells and eosinophils in BALF in a mouse model of allergic asthma at 3 and 10 mg/kg


Formal name: 1-[[[(1R)-1-[3-(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]-methyl]-cyclopropaneacetic acid, monosodium salt

Synonyms:  MK-476

Molecular weight: 608.2

CAS: 151767-02-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma||Research Area|Lipid Biochemistry|Lipoxygenase Pathways